来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

已收盘 12-19 16:08:47

9.100

-0.470

-4.91%

最高10.880	最低8.930	成交量1,938万
今开9.110	昨收9.570	日振幅20.38%
总市值37.13亿	流通市值37.13亿	总股本4.08亿
成交额1.90亿	换手率4.75%	流通股本4.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":9.1,"timestamp":1734595727014,"preClose":9.57,"halted":0,"volume":19380500,"delay":0,"floatShares":408000000,"shares":408000000,"eps":-1.8016791,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.47,"latestTime":"12-19 16:08:47","open":9.11,"high":10.88,"low":8.93,"amount":190064199,"amplitude":0.203762,"askPrice":9.12,"askSize":13000,"bidPrice":9.1,"bidSize":2500,"shortable":0,"etf":0,"ttmEps":-0.8896789716956189,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1687968000000,"adjPreClose":9.57,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":2.256997,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105","defaultTab":"news","newsList":[{"id":"2492157192","title":"来凯医药-B现涨超5% 此前宣布与礼来达成全球临床合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492157192","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492157192?lang=zh_cn&edition=full","pubTime":"2024-12-19 11:49","pubTimestamp":1734580140,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　来凯医药-B（02105）盘中涨超13%，截至发稿，股价上涨5.12%，现报10.06港元，成交额1.115亿港元。\n　　今年11月，来凯医药发布公告称，公司与礼来达成全球临床合作协议，礼来将负责在美国开展一项针对来凯减肥药LAE102的Ⅰ期临床研究，并承担相关费用。\n　　长城证券此前指出，以增肌减脂药物LAE102为代表的自研管线具备良好创新前景，看好公司产品未来商业化发展。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-19/doc-inczyhfz7039680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SG9999014906.USD","BK4516","LU0417517546.SGD","SG9999015952.SGD","LU1280957306.USD","LU2491049909.HKD","LU1814569148.SGD","LU2063271972.USD","LU2112291526.USD","SG9999015978.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU0094547139.USD","IE0004445239.USD","IE0002141913.USD","LU1868837300.USD","LU1983299246.USD","LU2361044949.HKD","LU0820561909.HKD","LU0079474960.USD","IE00BJLML261.HKD","LLY","LU1267930730.SGD","LU2361044865.SGD","SG9999015945.SGD","LU2089984988.USD","LU2106854487.HKD","LU0203201768.USD","LU1291159041.SGD","LU1093756325.SGD","LU2264538146.SGD","GB00BDT5M118.USD","LU2237443549.SGD","SG9999013999.USD","LU0203202063.USD","LU1551013425.SGD","LU1868836591.USD","LU1868837136.USD","LU0471298777.SGD","LU2468319806.SGD","LU0114720955.EUR","LU1974910355.USD","SG9999014898.SGD","IE00BFTCPJ56.SGD","02105","LU0256863902.USD","IE00BJT1NW94.SGD","LU0823416689.USD","LU2237443978.SGD","LU2237443622.USD"],"gpt_icon":0},{"id":"2492235194","title":"港股医药板块短线拉升，来凯医药(02105.HK)涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492235194","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492235194?lang=zh_cn&edition=full","pubTime":"2024-12-19 11:02","pubTimestamp":1734577335,"startTime":"0","endTime":"0","summary":"每经AI快讯，港股医药板块短线拉升，来凯医药(02105.HK)涨超6%，歌礼制药(01672.HK)涨超2%，开拓药业(09939.HK)、圣诺医药(02898.HK)跟涨。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412193273096038.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412193273096038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2492919919","title":"港股医药板块短线拉升，来凯医药(02105.HK)涨超6%，歌礼制药(01672.HK)涨超2%，开拓药业(09939.HK)、圣诺医药(02898.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492919919","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492919919?lang=zh_cn&edition=full","pubTime":"2024-12-19 10:57","pubTimestamp":1734577079,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","02898","01672","01477","02105","BK1515","BK1191","02257","09939","BK1574","159718"],"gpt_icon":0},{"id":"2492196912","title":"来凯医药-B盘中涨超13% 公司加快推动LAE102临床研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2492196912","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492196912?lang=zh_cn&edition=full","pubTime":"2024-12-19 10:29","pubTimestamp":1734575340,"startTime":"0","endTime":"0","summary":"　　来凯医药-B盘中涨超13%，截至发稿，股价上涨5.12%，现报10.06港元，成交额8280.22万港元。　　来凯医药本月初宣布，其自主研发的LAE102针对超重/肥胖在中国开展的I期临床试验进展顺利：单次剂量递增研究中的全部64名受试者，均已完成给药。来凯医药董事长兼首席执行官吕向阳博士表示，在完成I期临床试验的单剂量递增研究后，将按既定计划启动I期多剂量递增研究，以进一步评估耐受性和疗效，加快推动LAE102的临床研发及商务进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-19/doc-inczyhfz7006548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"1124459791","title":"异动解读 | 来凯医药盘中大涨逾13% 减肥药LAE102临床试验顺利推进引发市场看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1124459791","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124459791?lang=zh_cn&edition=full","pubTime":"2024-12-19 10:26","pubTimestamp":1734575211,"startTime":"0","endTime":"0","summary":"来凯医药-B(02105)今日盘中大涨逾13%,引发市场关注。消息面上,公司自主研发的LAE102(ActRIIA单克隆抗体)，针对超重/肥胖的I期临床试验进展顺利,单次剂量递增研究已顺利完成。\n\n公司将按既定计划启动I期多剂量递增研究,以进一步评估LAE102的耐受性和疗效,加快推动产品临床研发及商务进展。此外,来凯医药与礼来公司达成全球临床合作协议,礼来将负责在美国开展LAE102的I期临床研究。\n\n业内人士指出,LAE102作为来凯医药创新管线的代表产品,其临床进展顺利有望加速产品商业化进程,市场对公司长期发展前景持看好态度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02105"],"gpt_icon":0},{"id":"2492195781","title":"港股异动 | 来凯医药-B(02105)盘中涨超13% 公司加快推动LAE102临床研发 此前宣布与礼来在美国合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2492195781","media":"智通财经","labels":["corporation","productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492195781?lang=zh_cn&edition=full","pubTime":"2024-12-19 10:20","pubTimestamp":1734574852,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B盘中涨超13%，截至发稿，涨8.46%，报10.38港元，成交额7241.64万港元。来凯医药董事长兼首席执行官吕向阳博士表示，在完成I期临床试验的单剂量递增研究后，将按既定计划启动I期多剂量递增研究，以进一步评估耐受性和疗效，加快推动LAE102的临床研发及商务进展。今年11月，来凯医药发布公告称，公司与礼来达成全球临床合作协议，礼来将负责在美国开展一项针对来凯减肥药LAE102的Ⅰ期临床研究，并承担相关费用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0385154629.USD","SGXZ81514606.USD","IE00BK4W5L77.USD","LU1983299246.USD","LU1280957306.USD","SG9999013999.USD","IE00B2B36J28.USD","LU2023250504.SGD","LU0417517546.SGD","LU2491049909.HKD","LU0096364046.USD","LU1366192091.USD","LU2237443465.HKD","LU0114720955.EUR","LLY","BK4516","LU2602419157.SGD","LU0203201768.USD","LU1023059063.AUD","LU1989771016.USD","LU2106854487.HKD","LU0203202063.USD","LU1868836914.USD","BK1161","IE00BFTCPJ56.SGD","LU0079474960.USD","LU1127390331.HKD","LU0466842654.USD","LU0256863902.USD","LU0820561909.HKD","LU0456855351.SGD","LU0006306889.USD","LU1093756325.SGD","LU1267930730.SGD","LU2237438978.USD","SG9999015952.SGD","SGXZ31699556.SGD","IE00BJJMRZ35.SGD","SG9999018865.SGD","SG9999015986.USD","LU0882574055.USD","BK4599","LU2089984988.USD","BK4588","LU2237443895.HKD","LU0471298777.SGD","02105","LU0238689110.USD","LU0354030438.USD","LU2361045086.USD"],"gpt_icon":1},{"id":"2492928938","title":"港股部分医药股走弱，来凯医药-B跌超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492928938","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492928938?lang=zh_cn&edition=full","pubTime":"2024-12-18 11:30","pubTimestamp":1734492617,"startTime":"0","endTime":"0","summary":"南方财经12月18日电，港股部分医药股走弱，来凯医药-B跌超8%，为连续第五日下跌，刷新逾1个月低位；艾迪康控股、药师帮、科济药业-B等股跌幅居前。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412183271914271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","YANG","HSTECH","BK1515","BK1161","02105","HSCEI","09939"],"gpt_icon":0},{"id":"2492449049","title":"来凯医药-B盘中异动 早盘大幅下跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492449049","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492449049?lang=zh_cn&edition=full","pubTime":"2024-12-18 10:06","pubTimestamp":1734487601,"startTime":"0","endTime":"0","summary":"2024年12月18日早盘10时06分，来凯医药-B股票出现异动，股价快速跳水5.04%。截至发稿，该股报9.800港元/股，成交量128.35万股，换手率0.31%，振幅6.20%。来凯医药-B股票所在的生物技术行业中，整体涨幅为0.57%。其相关个股中，歌礼制药-B、圣诺医药-B、百奥赛图-B涨幅较大，振幅较大的相关个股有永泰生物-B、帝王国际投资、歌礼制药-B，振幅分别为14.23%、13.73%、12.61%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218100644a1f74789&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218100644a1f74789&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2492608803","title":"来凯医药-B盘中异动 早盘大幅跳水5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492608803","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492608803?lang=zh_cn&edition=full","pubTime":"2024-12-17 10:04","pubTimestamp":1734401080,"startTime":"0","endTime":"0","summary":"2024年12月17日早盘10时04分，来凯医药-B股票出现波动，股价急速下挫5.17%。截至发稿，该股报10.280港元/股，成交量122.05万股，换手率0.30%，振幅5.17%。来凯医药-B股票所在的生物技术行业中，整体涨幅为0.22%。其相关个股中，华昊中天医药-B、帝王国际投资、和铂医药-B涨幅较大，振幅较大的相关个股有晶泰控股-P、科济药业-B、华昊中天医药-B，振幅分别为15.90%、11.61%、9.01%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217100440a1f481d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217100440a1f481d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2491630509","title":"医药股多数承压 来凯医药(02105)跌近11% 机构指板块当前已经处于业绩、政策和资金三重反转的进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2491630509","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491630509?lang=zh_cn&edition=full","pubTime":"2024-12-16 14:56","pubTimestamp":1734332198,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股多数承压，来凯医药 跌10.94%，康诺亚跌6.07%，金斯瑞生物科技跌5.54%，科伦博泰生物跌4.96%，康方生物跌4.4%，药明生物跌3.15%。国金证券发研指，医药板块当前已经处于业绩、政策和资金三重反转的进程之中，对2025年医药板块上市公司营收利润增速回升、板块行情复苏有充分信心。医保局将指导各地及中选企业做好中选结果落地实施工作，确保全国患者于2025年4月用上本次集采中选产品。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949709","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0043850808.USD","LU0516423091.SGD","BK1576","LU0456827905.SGD","02162","06990","LU0348735423.USD","LU0516422952.EUR","HK0000306685.HKD","IE00B0JY6N72.USD","LU0417516571.SGD","LU0823426308.USD","LU0359201612.USD","LU1242518857.USD","LU0572944931.SGD","LU1720050803.USD","HK0000320223.HKD","SG9999002463.SGD","LU0326950275.SGD","01548","09939","LU0051755006.USD","LU0456846285.SGD","LU0181495838.USD","09926","LU0516422366.SGD","LU1880383366.USD","LU0516423174.USD","IE00B5MMRT66.SGD","LU0588546209.SGD","BK1583","LU0320764599.SGD","LU0348825331.USD","LU0979878070.USD","HK0000306701.USD","BK1521","02105","LU0348784397.USD","LU2488822045.USD","LU0348783233.USD","LU1242518931.SGD","LU0140636845.USD","02269","BK1587","LU2039709279.SGD","LU0307460666.USD","LU0359202008.SGD","159938","BK1574","LU0823426480.USD"],"gpt_icon":1},{"id":"2491394376","title":"来凯医药－Ｂ(02105)出现大手买入47.6万股，成交价$10.8，涉资514.08万","url":"https://stock-news.laohu8.com/highlight/detail?id=2491394376","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491394376?lang=zh_cn&edition=full","pubTime":"2024-12-16 13:03","pubTimestamp":1734325380,"startTime":"0","endTime":"0","summary":"[大手成交]来凯医药－Ｂ(02105)在下午01:03出现大手买入，成交量为47.6万，成交价为港币$10.8，涉资514.08万。至目前为止，股价跌9.091%，今日最高价为$12.08，而最低价为$10.6，总成交量为692.4万股，总成交金额港币$7.647千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2412164683/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2491818806","title":"来凯医药-B盘中异动 早盘急速跳水5.05%报11.280港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491818806","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491818806?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:42","pubTimestamp":1734313355,"startTime":"0","endTime":"0","summary":"2024年12月16日早盘09时42分，来凯医药-B股票出现波动，股价快速下挫5.05%。截至发稿，该股报11.280港元/股，成交量85.2万股，换手率0.21%，振幅6.73%。资金方面，该股资金流入343.222万港元，流出516.516万港元。来凯医药-B股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，东曜药业-B、云康集团、百奥赛图-B涨幅较大，振幅较大的相关个股有创胜集团-B、加科思-B、永泰生物-B，振幅分别为18.03%、11.59%、9.09%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121609423595e9f725&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121609423595e9f725&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2491343501","title":"来凯医药-B12月13日主力资金流出536万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2491343501","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491343501?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:16","pubTimestamp":1734077791,"startTime":"0","endTime":"0","summary":"12月13日, 来凯医药-B股价跌9.17%，报收11.88元，成交金额8384万元，换手率1.68%，振幅13.76%，量比0.85。来凯医药-B今日主力资金净流出536万元，连续3日净流出，上一交易日主力净流出323万元，今日环比增加65.94%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为66.67%，平均跌幅为8.98%。该股近5个交易日下跌17.59%，主力资金累计净流出1151万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出2490万元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161716ab74c0d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161716ab74c0d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2490871994","title":"来凯医药-B12月12日遭主力抛售323万元 环比增加3130.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490871994","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490871994?lang=zh_cn&edition=full","pubTime":"2024-12-12 16:16","pubTimestamp":1733991399,"startTime":"0","endTime":"0","summary":"12月12日, 来凯医药-B股价跌4.80%，报收13.08元，成交金额1.03亿元，换手率1.90%，振幅10.77%，量比0.95。来凯医药-B今日主力资金净流出323万元，上一交易日主力净流出10万元，今日环比增加3130.00%。该股近5个交易日下跌2.09%，主力资金累计净流出622万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出2057万元，其中净流出天数为13日。该股主力净额占比0.06%，港股市场排名2592/2652。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212161743ab71df32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212161743ab71df32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2490259821","title":"来凯医药-B盘中异动 急速下跌5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490259821","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490259821?lang=zh_cn&edition=full","pubTime":"2024-12-12 13:39","pubTimestamp":1733981940,"startTime":"0","endTime":"0","summary":"2024年12月12日下午盘13时39分，来凯医药-B股票出现波动，股价快速下挫5.24%。截至发稿，该股报13.020港元/股，成交量440.45万股，换手率1.08%，振幅9.32%。来凯医药-B股票所在的生物技术行业中，整体跌幅为0.40%。其相关个股中，思路迪医药股份、晶泰控股-P、帝王国际投资涨幅较大，振幅较大的相关个股有思路迪医药股份、晶泰控股-P、帝王国际投资，振幅分别为38.70%、19.44%、18.75%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212133900a1e83095&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212133900a1e83095&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2491357563","title":"来凯医药自主研发PI3Kα抑制剂入选2024 SABCS具同类最佳潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2491357563","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491357563?lang=zh_cn&edition=full","pubTime":"2024-12-12 08:30","pubTimestamp":1733963400,"startTime":"0","endTime":"0","summary":"上海2024年12月12日 /美通社/ -- 来凯医药 今日宣布，公司自主研发成果\"一种针对多类PI3Kα突变型的变构抑制剂—— LAE118 的临床前研究\"，已入选2024圣安东尼奥乳腺癌研讨会，将于12月13日在美国德克萨斯州圣安东尼奥的研讨会上以壁报形式展示相关研究数据。然而，目前已获批的PI3Kα 抑制剂可同时抑制野生型，对突变型没有选择性。与正构PI3Kα 抑制剂相比，LAE118对血糖和胰岛素的影响更小。LAE102是来凯自主研发针对ActRIIA的单克隆抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4577411_ZH77411_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"1139277131","title":"异动解读 | 来凯医药-B(2105.HK)盘中大涨5.58%,获市场认可和创新药物前景双驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=1139277131","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139277131?lang=zh_cn&edition=full","pubTime":"2024-12-11 13:06","pubTimestamp":1733893603,"startTime":"0","endTime":"0","summary":"来凯医药-B在2024年12月11日周三盘中大涨5.58%,引发市场关注。本次股价大涨的主要原因有两个方面:一是来凯医药在年度颁奖典礼上获得多项殊荣,获得了市场的高度认可;二是公司在新药研发方面取得重大进展,新药前景广阔。11月份,全球药企礼来还与来凯医药达成合作,支持并加速LAE102的临床开发。新药管线的不断推进,充分展现了来凯医药持续创新的实力和长期价值潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 来凯医药-B(2105.HK)盘中大涨5.58%,获市场认可和创新药物前景双驱动","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02105"],"gpt_icon":0},{"id":"2490007767","title":"来凯医药-B盘中异动 下午盘大幅上涨5.28%报13.960港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490007767","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490007767?lang=zh_cn&edition=full","pubTime":"2024-12-11 13:04","pubTimestamp":1733893458,"startTime":"0","endTime":"0","summary":"2024年12月11日下午盘13时04分，来凯医药-B股票出现波动，股价大幅上涨5.28%。截至发稿，该股报13.960港元/股，成交量344万股，换手率0.84%，振幅10.26%。资金方面，该股资金流入2190.27万港元，流出1623.48万港元。来凯医药-B股票所在的生物技术行业中，整体跌幅为0.44%。其相关个股中，科济药业-B、北海康成-B、思路迪医药股份涨幅较大，振幅较大的相关个股有北海康成-B、科济药业-B、创胜集团-B，振幅分别为45.77%、18.69%、14.29%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211130419ab6e9283&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211130419ab6e9283&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2490004462","title":"“第九届智通财经资本市场年会暨上市公司颁奖典礼”26项大奖揭晓：245家公司分获殊荣!","url":"https://stock-news.laohu8.com/highlight/detail?id=2490004462","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490004462?lang=zh_cn&edition=full","pubTime":"2024-12-11 12:31","pubTimestamp":1733891515,"startTime":"0","endTime":"0","summary":"2024年12月11日上午，“第九届智通财经资本市场年会暨上市公司颁奖典礼” 在深圳隆重开幕。“第九届智通财经上市公司评选”自2016年启动以来，已连续成功举办9届。接近岁末，在全球资本的版图中，港股市场再度成为焦点。截至11月底，南向资金已连续17个月净流入，年内净买入总额突破7300亿港元，创下10年新高。剔除重复获奖，本届上市公司颁奖典礼共有245家公司及其高管分享这些荣誉。评选期间，吸引了超过1000家港美股上市公司积极参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01783","01598","02018","06122","01880","06633","01735","00826","02020","00291","01450","02100","01093","02171","00780","00799","00017","00855","01405","01117","00451","00268","01651","00798","01427","01471","02225","02137","02145","01378","00460","01121","09919","01083","02158","09896","06058","06677","01969","02105","06682","00003","01907","00552","01992","01519","02013","06680","06086"],"gpt_icon":0},{"id":"2490710890","title":"斩获“港股通最受欢迎企业”，来凯医药-B（2105.HK）如何用增肌减脂药诠释创新价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2490710890","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490710890?lang=zh_cn&edition=full","pubTime":"2024-12-11 08:45","pubTimestamp":1733877951,"startTime":"0","endTime":"0","summary":"荣获“年度港股通最受欢迎企业”奖项以及“年度卓越IR团队”奖项。","market":"hk","thumbnail":"https://img7.gelonghui.com/column/3.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/3.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1461021","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["HSCEI","BK1161","YANG","02105","HSTECH"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":-0.3035},{"period":"1month","weight":-0.1056},{"period":"3month","weight":1.1362},{"period":"6month","weight":0.6878},{"period":"1year","weight":-0.5021},{"period":"ytd","weight":-0.5191}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症、肝脏疾病及肥胖症创新疗法的发现、开发及商业化的投资控股公司。该公司尚处于研发阶段。该公司的在研管线产品包括Afuresertib（LAE002）、LAE001、LAE109、LAE111、LAE112、LAE113、LAE117、LAE118、LAE119、LAE102、LAE103、LAE104、LAE105、LAE106、LAE107、LAE120、LAE123等。Afuresertib是一种三磷酸腺苷（ATP）竞争性AKT抑制剂。LAE001是雄激素合成抑制剂，可同时抑制CYP17A1及CYP11B2。该公司主要在中国、美国、欧洲、韩国等市场开展业务。","exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}